Registry for Hypertrophic Cardiomyopathy

Overview

About this study

The purpose of this study is to refine identification of the clinical, imaging, biomarker and genetic variables that predict risk of the primary adverse clinical outcomes in HCM.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All patients enrolled in the original study will be invited to continue follow-up.

Exclusion Criteria:

Not enrolled in original study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/3/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Jeffrey Geske, M.D.	Open for enrollment	Contact information: Kathy Brown (507) 538-1321 brown.kathy@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jeffrey Geske, M.D.

Open for enrollment

Contact information:

Kathy Brown

(507) 538-1321

brown.kathy@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials